

**Table 4.1**  
**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for MRC Super Cohort Participants<sup>1</sup> Who Did Not Report a Prevalent Condition at Baseline**

Data as of: March 1, 2019; Events through March 1, 2019

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number of participants</b>	44174	6788	9352	19418	8616
<b>Mean follow-up (months)</b>	177.0	188.8	189.7	178.2	151.3
Angina (hospitalized) <sup>2</sup>	3352 (0.54%)	422 (0.41%)	616 (0.43%)	1614 (0.59%)	700 (0.70%)
Diabetes (treated)	7768 (1.27%)	1369 (1.34%)	1773 (1.27%)	3504 (1.30%)	1122 (1.10%)
Hysterectomy	1880 (0.50%)	300 (0.52%)	471 (0.53%)	842 (0.51%)	267 (0.44%)
Osteoarthritis <sup>3</sup>	13521 (3.33%)	2319 (2.91%)	3130 (3.09%)	5922 (3.47%)	2150 (3.90%)
Intestinal polyps	10634 (1.76%)	1745 (1.70%)	2519 (1.80%)	4843 (1.82%)	1527 (1.59%)
Lupus	804 (0.12%)	129 (0.12%)	179 (0.12%)	368 (0.13%)	128 (0.12%)
Hypertension treated w/pills	16376 (3.71%)	2676 (3.26%)	3646 (3.43%)	7175 (3.84%)	2879 (4.41%)
COPD <sup>4</sup>	2430 (0.83%)	340 (0.70%)	567 (0.86%)	1214 (0.95%)	309 (0.66%)
Macular degeneration <sup>5</sup>	4779 (1.05%)	400 (0.52%)	809 (0.77%)	2399 (1.20%)	1171 (1.62%)
Dementia <sup>5</sup>	4305 (0.94%)	247 (0.32%)	522 (0.50%)	2175 (1.09%)	1361 (1.89%)
Parkinson's disease <sup>5</sup>	592 (0.13%)	60 (0.08%)	116 (0.11%)	307 (0.15%)	109 (0.15%)

Outcomes	Race/Ethnicity					
	American Indian/ Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/ Latina	White	Unknown
<b>Number of participants</b>	130	527	14618	6484	22030	385
<b>Mean follow-up (months)</b>	169.0	171.4	162.3	153.4	193.9	177.9
Angina (hospitalized) <sup>2</sup>	16 (0.95%)	22 (0.31%)	1033 (0.56%)	343 (0.43%)	1901 (0.56%)	37 (0.68%)
Diabetes (treated)	25 (1.53%)	92 (1.30%)	2895 (1.63%)	1123 (1.44%)	3558 (1.04%)	75 (1.41%)
Hysterectomy	4 (0.54%)	12 (0.23%)	440 (0.50%)	281 (0.61%)	1126 (0.49%)	17 (0.48%)
Osteoarthritis <sup>3</sup>	48 (3.84%)	175 (3.24%)	4039 (3.44%)	2033 (3.67%)	7099 (3.18%)	127 (3.40%)
Intestinal polyps	33 (1.94%)	109 (1.61%)	3536 (1.93%)	1309 (1.67%)	5561 (1.68%)	86 (1.65%)
Lupus	3 (0.16%)	6 (0.08%)	290 (0.15%)	131 (0.16%)	370 (0.10%)	4 (0.07%)
Hypertension treated w/pills	58 (4.37%)	190 (3.57%)	4402 (4.38%)	2347 (3.72%)	9244 (3.47%)	135 (3.42%)
COPD <sup>4</sup>	10 (1.32%)	13 (0.36%)	616 (0.64%)	224 (0.50%)	1549 (1.07%)	18 (0.72%)
Macular degeneration <sup>5</sup>	15 (1.12%)	41 (0.81%)	881 (0.59%)	490 (0.74%)	3312 (1.44%)	40 (1.01%)
Dementia <sup>5</sup>	12 (0.89%)	38 (0.76%)	1047 (0.71%)	443 (0.67%)	2737 (1.19%)	28 (0.71%)
Parkinson's disease <sup>5</sup>	2 (0.15%)	8 (0.16%)	147 (0.10%)	62 (0.09%)	368 (0.16%)	5 (0.13%)

<sup>1</sup> The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

<sup>2</sup> During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

<sup>3</sup> This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>4</sup> Data only collected during the WHI Extension Study 2010-2020.

<sup>5</sup> Data only collected during the WHI Extension Studies 2005-2020.